• Je něco špatně v tomto záznamu ?

Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family

J. Hercogová, M. Tirant, P. Bayer, M. Coburn, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,

. 2016 ; 30 (2 Suppl 3) : 89-93.

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001366

Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.

000      
00000naa a2200000 a 4500
001      
bmc19001366
003      
CZ-PrNML
005      
20190308113930.0
007      
ta
008      
190107s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27498664
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family / $c J. Hercogová, M. Tirant, P. Bayer, M. Coburn, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,
520    9_
$a Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.
650    _2
$a aplikace kožní $7 D000279
650    _2
$a senioři $7 D000368
650    _2
$a kandidóza kožní $x komplikace $x farmakoterapie $x patologie $7 D002179
650    _2
$a komplementární terapie $x metody $7 D000529
650    _2
$a diabetes mellitus 2. typu $x komplikace $7 D003924
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intertrigo $x komplikace $x farmakoterapie $x patologie $7 D007402
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a obezita $x komplikace $7 D009765
650    _2
$a masti $x aplikace a dávkování $x terapeutické užití $7 D009824
650    12
$a fytoterapie $7 D008517
650    _2
$a kůže $x účinky léků $x patologie $7 D012867
650    _2
$a péče o kůži $x metody $7 D017592
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Bayer, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Coburn, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Donnelly, B $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Kennedy, T $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Gaibor, J $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Arora, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Clews, L $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy.
700    1_
$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.
700    1_
$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
700    1_
$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
700    1_
$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
700    1_
$a Novotny, F $u PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
700    1_
$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
700    1_
$a Maximov, G K $u Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria.
700    1_
$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
700    1_
$a Lotti, T $u Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
773    0_
$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 89-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27498664 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190308114245 $b ABA008
999    __
$a ok $b bmc $g 1364063 $s 1039489
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 Suppl 3 $d 89-93 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace